巴曲酶、尿激酶联合应用对局灶性脑缺血再灌注大鼠颅内出血的影响

目的 探讨巴曲酶和尿激酶联合使用能否减少颅内出血并发症。方法 采用大鼠大脑中动脉闭塞(MCAO)线栓法模型，将大鼠随机分为对照组、假手术组、单独或联合使用巴曲酶和尿激酶组，共9组，每组15只。观察颅内出血、脑梗塞体积和神经功能缺损情况。结果 尿激酶5000U／kg组有5只颅内出血。巴曲酶5BU／kg(2h) 尿激酶5000U／kg(2h)组有4只颅内出血，巴曲酶5BU／kg(1h) 尿激酶5000U／kg(2h)组有1只颅内出血。巴曲酶5BU／kg(2h)组、巴曲酶10BU／kg(2h) 尿激酶2500U／kg(2h)组可缩小梗塞体积比。各组神经功能缺损无明显差异。结论 5000U／kg尿激酶造成颅内出血增加。单独使用巴曲酶颅内出血不增加，巴曲酶和尿激酶联合应用不增加颅内出血。

Effectiveness of Urokinase Used in Combination with Batroxobin(DF-521) in Rat Model of Focal Cerebral Ischemia-Reperfusion

Objective This study was designed to use urokinase(UK) in combination with batroxobin in thrombolytic therapy so as to see whether batroxobin(DF-521) would be effective for neuroprotection. Methods The model of right middle cerebral artery occlusion (MCAO) in male SD rats was established. 120 rats were randomized into 9 groups, namely control group, sham control group, and groups that were treated with batroxobin and urokinase together or separately. Each group comprised 15 rats. Intracranial bleeding, infarct volume ratio and neurological function were observed. Results Intracranial bleeding was found in 5 rats of the UK 5000 U/kg group, in 4 rats of the UK 5000 U/kg (2 h)+DF-521 5 BU/kg(2 h) group, and in only 1 rat of the UK 5000 U/kg (2 h)+DF-521 5 BU/kg(1 h) group. Cerebral infarct volume ratio was obviously reduced in 5 BU/kg batroxobin group. No difference was observed in neurological deficit scores. Conclusion 5000 U/kg urokinase increased the risk of intracranial hemorrhage in rat MCAO model. Batroxobin either used separately or in combination with urokinase would not increase the risk of intracranial hemorrhage in rat MCAO model.